```html

Yellow Lymphoma (Hodgkin’s Lymphoma, Nodular Sclerosis Subtype)

Overview

Yellow lymphoma is an informal term sometimes used to describe the classic “yellow‑colored” appearance of the fibrous bands seen in the **nodular sclerosis subtype of classical Hodgkin lymphoma (cHL‑NS)** when examined under a microscope. It is not a separate disease; it is a histologic variant of Hodgkin lymphoma that accounts for roughly ~70% of all Hodgkin lymphoma cases in the United States [1].

Key points:

• What it is: A cancer of the lymphatic system that originates from B‑lymphocytes. The nodular sclerosis subtype is characterized by the presence of Reed‑Sternberg cells surrounded by collagen bands that give a “nodular” pattern.
• Typical age group: Bimodal distribution – peaks in late teens/early 20s and again in the 50‑70‑year age range.
• Gender: Slight female predominance (≈55% female).
• Prevalence: Hodgkin lymphoma overall affects about 2.6 per 100,000 people worldwide each year; nodular sclerosis makes up roughly 60‑70% of those cases [2].

Symptoms

Symptoms develop gradually and may be mistaken for a simple infection. Not every person experiences all of them.

Common early signs

• Painless swelling of lymph nodes – usually in the neck, under the arms, or above the collarbone.
• Fatigue – persistent tiredness not relieved by rest.
• Unexplained weight loss – >10 % of body weight over 6 months.
• Fever – low‑grade, often “drunken” (intermittent) fevers.
• Night sweats – soaking sweats that require changing bedding.

Symptoms related to disease location

• Chest discomfort or cough – when mediastinal (central chest) lymph nodes are involved, which occurs in ~70 % of nodular sclerosis cases.
• Difficulty swallowing or shortness of breath – due to compression of the airway or esophagus.
• Abdominal pain or swelling – if abdominal nodes are enlarged.
• Itching (pruritus) – diffuse or localized, reported in up to one‑third of patients.

Less common but important clues

• Persistent headache or neurological symptoms (rare, indicates central nervous system involvement).
• Bone pain or fractures (very rare, suggests disease spread to bone).

Causes and Risk Factors

Exact cause of Hodgkin lymphoma remains unknown, but several factors increase risk.

Genetic and biological factors

• Family history: First‑degree relatives with Hodgkin lymphoma increase risk 2‑3 times [3].
• HLA type: Certain human leukocyte antigen (HLA) alleles are associated with higher susceptibility.
• Epstein‑Barr virus (EBV) infection: EBV DNA is found in the Reed‑Sternberg cells of ~30‑50 % of nodular‑sclerosis cases, especially in younger patients [4].

Environmental and lifestyle factors

• Previous infection: Early childhood infections (e.g., measles, varicella) may modulate immune response.
• Immunosuppression: HIV infection or long‑term immunosuppressive therapy slightly raises risk.
• Occupational exposure: Rarely, exposure to radiation or certain chemicals (e.g., pesticides) has been linked.
• Smoking: Data are mixed; some studies suggest a modest increase, particularly for mediastinal disease.

Diagnosis

Diagnosing nodular sclerosis Hodgkin lymphoma requires a combination of clinical evaluation, imaging, and tissue sampling.

Initial work‑up

• Physical examination: Palpation of enlarged lymph nodes, assessment of spleen and liver size.
• Blood tests: Complete blood count, ESR, LDH, liver/kidney function, and viral serologies (EBV, HIV).

Imaging studies

• Chest X‑ray: Detects mediastinal mass.
• Contrast‑enhanced CT scan: Defines the size and distribution of nodal disease (neck, chest, abdomen, pelvis).
• PET‑CT (FDG‑PET): Gold standard for staging; highlights metabolically active disease and guides treatment response [5].
• MRI: Used when CNS or spinal involvement is suspected.

Definitive tissue diagnosis

• Excisional lymph node biopsy: Preferred method – the entire node is removed, preserving architecture for histology.
• Core needle biopsy: Acceptable if excision is not feasible, but may be insufficient for subclassification.
• Pathology findings:
  • Reed‑Sternberg “owl‑eye” cells (CD30+, CD15+, PAX5 weak).
  • Collagen bands dividing the node into nodules – hallmark of nodular sclerosis.
  • Immunohistochemistry and EBV-encoded RNA (EBER) in situ hybridization when EBV is suspected.

Staging

The Ann Arbor system (Stage I‑IV) with “A” (no B‑symptoms) or “B” (presence of fever, night sweats, weight loss) modifiers is used. A “bulky” disease designation (mass >10 cm or >1/3 of thoracic diameter) influences treatment intensity.

Treatment Options

Therapy is curative in >80 % of patients when appropriately staged and treated.

First‑line chemotherapy

• ABVD regimen (Adriamycin/doxorubicin, Bleomycin, Vinblastine, Dacarbazine) – standard for most early‑stage disease. 6–8 cycles are typical [6].
• Escalated BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) – used for advanced or high‑risk disease; higher cure rates but more toxicity.

Radiation therapy

• Involved‑field radiotherapy (IFRT): 20‑30 Gy to initially involved sites, especially for stage I/II disease.
• Modern techniques (IMRT, proton therapy) reduce exposure to heart and lungs.

Targeted and immunotherapy (relapsed/refractory cases)

• Brentuximab vedotin (Adcetris): CD30‑directed antibody‑drug conjugate; approved after failure of ≥1 chemotherapy line.
• PD‑1 inhibitors (nivolumab, pembrolizumab): Show durable responses in 60‑70 % of relapsed cHL patients [7].

Stem cell transplantation

High‑dose chemotherapy followed by autologous hematopoietic stem cell rescue is standard for chemosensitive relapsed disease.

Supportive care & lifestyle adjuncts

• Growth factor support (filgrastim) for neutropenia.
• Antiemetics, hydration, and nutrition counseling.
• Vaccinations (influenza, pneumococcal) after treatment, per CDC guidelines.

Living with Yellow Lymphoma (Hodgkin’s lymphoma, nodular sclerosis subtype)

Even after successful treatment, many patients face physical, emotional, and practical challenges.

Follow‑up schedule

• First 2 years: clinical exam and PET/CT every 3–6 months.
• Years 3‑5: every 6–12 months.
• After 5 years: annually, focusing on secondary malignancy screening (breast, thyroid, lung).

Managing side effects

• Fatigue: Gentle exercise (e.g., walking 20‑30 min most days) improves stamina.
• Peripheral neuropathy (from vinblastine/bleomycin): Hand‑eye coordination exercises and temperature protection.
• Cardiac monitoring: Doxorubicin can cause cardiomyopathy; get an echocardiogram baseline and then every 2–3 years.
• Thyroid function: Radiation to neck can induce hypothyroidism; check TSH annually.

Psychosocial support

• Join a lymphoma survivor group—shared experience reduces isolation.
• Consider counseling for anxiety or “chemo‑brain” cognitive changes.
• Financial navigation services can assist with insurance and work‑leave issues.

Healthy lifestyle tips

• Balanced diet rich in fruits, vegetables, lean protein, and whole grains.
• Maintain a healthy weight (BMI 18.5‑24.9) to lessen cardiovascular risk.
• Avoid tobacco and limit alcohol (<2 drinks/day for men, <1 for women).
• Stay physically active – at least 150 minutes of moderate aerobic activity weekly.

Prevention

Because the precise cause is uncertain, primary prevention is limited, but risk can be reduced by general health measures:

• Vaccinate against Epstein‑Barr virus–associated diseases where available (no specific EBV vaccine yet).
• Practice safe sex and avoid sharing needles to reduce HIV infection risk.
• Limit exposure to ionizing radiation (e.g., unnecessary CT scans) when possible.
• Maintain a strong immune system through adequate sleep, nutrition, and regular exercise.

Complications

If left untreated or poorly managed, nodular‑sclerosis Hodgkin lymphoma can lead to serious health problems.

• Progressive organ compression: Mediastinal mass may cause superior vena cava syndrome, respiratory failure.
• Secondary infections: Due to chemotherapy‑induced neutropenia.
• Infertility: Alkylating agents (e.g., cyclophosphamide) and radiation can affect gonadal function; fertility preservation is advised before treatment.
• Late effects: Secondary solid tumors (breast, lung, thyroid), cardiovascular disease, and pulmonary fibrosis (from bleomycin).
• Psychiatric sequelae: Depression, post‑traumatic stress, and chronic fatigue syndrome.

When to Seek Emergency Care

---

Sources: 1. American Cancer Society. Hodgkin Lymphoma Statistics. 2024.
2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th Ed., 2022.
3. Swerdlow SH, et al. “Familial Hodgkin lymphoma.” Blood. 2021.
4. Jarrett RF, et al. “EBV and Hodgkin lymphoma.” Nat Rev Cancer. 2022.
5. National Comprehensive Cancer Network (NCCN) Guidelines, Version 2.2024 – Hodgkin Lymphoma.
6. Connors JM, et al. “ABVD versus BEACOPP for advanced Hodgkin lymphoma.” J Clin Oncol. 2023.
7. Ansell SM, et al. “PD‑1 blockade in relapsed Hodgkin lymphoma.” Lancet. 2022.
8. CDC. Vaccination Recommendations for Immunocompromised Adults. Updated 2024.
9. Mayo Clinic. Hodgkin Lymphoma: Diagnosis and treatment. 2023.

```